University Of California, San Francisco

University Of California, San Francisco, doing business as UCSF Medical Center Administration, is a tax-exempt nonprofit academic medical center and child entity of the State of California Controllers Office that delivers clinical research services, medical device procurement, and specialized healthcare support to federal agencies as a prime contractor (71% of recent awards) and as a subcontractor on biomedical research grants. UCSF competes full-and-open without set-aside designations across its federal footprint.

UCSF's federal work splits sharply between research and medical device procurement. The National Heart Lung and Blood Institute anchors its research capability through a $49.7 million single-award Indefinite Delivery Contract for the SPIROMICS III chronic obstructive pulmonary disease study, which runs through June 2031 and includes two major task orders: a $6.7 million delivery order for Task Area A and a $1.2 million delivery order for Task Area B, both cost-no-fee arrangements. In medical devices, UCSF holds a dominant position with the Department of Veterans Affairs, Veterans Integrated Service Network 21, where 26 awards valued at $626 thousand represent routine firm fixed-price purchase orders for prosthetic limbs (above-knee, below-knee, hip, and leg prostheses), research assistance delivery orders under a $53 thousand single-award IDC running through September 2026, and specialized clinical services including osteoporosis bone scans and genomics collaboration. Recent examples include a $42.7 thousand purchase order for lower limb prosthetics (July 2025), a $50.4 thousand purchase order for right hip prostheses (March 2025), and a $19.2 thousand delivery order for research assistance (September 2024). Outside VA work, UCSF received a $500 thousand firm fixed-price definitive contract from the Food and Drug Administration awarded September 30, 2026 for development of a multi-agent artificial intelligence system for high-throughput physiologically-based pharmacokinetic modeling predicting formulation effects on drug absorption through March 2028, and a $173.3 thousand purchase order from the Office of the Assistant Secretary for Administration (September 2024) supporting communication, participant engagement, and evaluation of a Newborn Supply Kit Pilot program focused on maternal mental health outcomes.

Customer concentration is heavily weighted toward the Department of Veterans Affairs and the National Institutes of Health. The top five funding agencies account for 75% of awards by count; the VA alone represents 26 awards but only $626 thousand in combined potential value, while the National Heart Lung and Blood Institute's four awards carry $49.7 million in combined potential value—a stark divergence indicating numerous small transactional VA device procurements anchoring volume while research funding concentrates dollars. UCSF maintains positions on two parent Indefinite Delivery Contracts with combined task-order activity: a $51 thousand vehicle (36C24E23D0040) with three task orders and a vehicle (75N92024D00012) with two task orders.

Activity has grown from three awards in 2022 to sixteen in 2024, with one award currently scheduled for completion within the next twenty-four months (the $500 thousand FDA contract completing March 2028 is beyond the recompete cliff). UCSF's subcontractor footprint centers on biomedical research grants under prime grantees including New York University (advancing precision psychiatry for military service-related PTSD, employing gut microbiome for rheumatoid arthritis therapy, surveillance and treatment for fetal atrioventricular block, and online prostate cancer information disparities research), Loyola University of Chicago (novel exosomal niches for alveolar stem cell-based repair of acute respiratory distress syndrome), and Northern California Institute for Research and Education (axial spondyloarthritis cohort leadership). UCSF also acts as a sub-recipient on disaster-recovery and public-health grants from the Office of Emergency Services and City and County of San Francisco, including debris removal, emergency protective measures, and overdose fatality review program implementation. The institution's federal award footprint reflects its primary capability profile: precision-medicine research (COPD, rheumatoid arthritis, PTSD, cardiovascular conditions), orthopedic device provision to the VA health system, and federally sponsored biomedical research infrastructure.